GSK Rebuts Teva’s ‘Doomsday Scenario’ On Skinny-Label Generics
Originator Urges US Supreme Court To Reject Review Of Indication Carve-Out Lawsuit
GSK has lodged its opposition to Teva’s bid to resurrect long-running US litigation over “skinny-label” indication carve-outs at the Supreme Court level, claiming that Teva’s warnings of a “doomsday scenario” for generics are overstated.
